LONDON – U.S. scientists are calling for a rethink of current restrictions on using CRISPR/Cas9 gene editing in human embryos after successfully correcting the MYBPC3 hypertrophic cardiomyopathy mutation, the commonest cause of heart failure and sudden death in apparently healthy young people, without causing any off-target effects or mosaicism.